PMH35: ATYPICAL ANTIPSYCHOTICS:TREATMENT PATTERNS, UTILIZATION AND COST AMONG MANAGED CARE ENROLLEES  by Hall, JA et al.
355Abstracts
OBJECTIVE: To determine whether or not subtle differ-
ences between risperidone and olanzapine, two similarly-
efﬁcacious medications, are reﬂected in health care
utilization patterns, and therefore, costs, in patients with
schizophrenia receiving usual care. METHODS: A retro-
spective cohort study was conducted from the payer per-
spective in two group model managed care organizations.
Analysis of covariance and logistic regression were used
to identify outpatient cost and hospitalization differences
respectively, while adjusting for variables that may inde-
pendently inﬂuence mental health utilization and choice
of atypical agent. Patients ages 18–64 initiating risperi-
done or olanzapine between January 1997 and December
2000 diagnosed with schizophrenia or schizoaffective 
disorder in the pre-initiation year were included if they
received no atypical antipsychotics in the previous year
and were continuously enrolled one year pre through one
year post initiation. Utilization units were transformed
into 2001 costs at one site. The total post-initiation year
outpatient mental health cost derived included all mental
health outpatient visits (including urgent care) and med-
ications, and tests related to olanzapine or risperidone
monitoring. The relationship between drug exposure and
hospitalization was explored using logistic regression. 
An intent-to-treat analysis was performed. RESULTS:
Patients receiving risperidone were less costly in the post-
initiation year than patients receiving olanzapine. The
results were signiﬁcant (p < 0.05) controlling for age,
gender, coverage type, total mental health outpatient costs
in the year prior to initiation, study site, index year,
mental health comorbidities, and mental health hospital-
ization in the pre-initiation year. Seventeen percent of
olanzapine and 21% of risperidone patients were hospi-
talized in the year post initiation, a difference that was
not statistically signiﬁcant. CONCLUSIONS: Prescribers
should consider using risperidone before using olanzap-
ine when initiating therapy in a patient with schizophre-
nia who has no contraindications to either medication.
More study is needed to determine the relation-
ship between atypical choice and mental health 
hospitalization.
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OBJECTIVE: To compare pharmacotherapy patterns 
and treatment outcomes for olanzapine- versus quetia-
pine-treated hospitalized patients with schizophrenia.
METHODS: Hospitalized olanzapine- and quetiapine-
treated patients discharged with schizophrenia (ICD9:
295.xx) between 01/1999 and 09/2001 were identiﬁed
using Premier’s PerspectiveTM database, the largest U.S.
hospital drug utilization database. Outcome measures
include use of other antipsychotics, mood stabilizers, anti-
depressants, anxiolytics, and hypnotics; length of stay
(LOS); and total treatment costs were analyzed by regres-
sions, controlling diagnoses, illness severity, patient and
institution characteristics. RESULTS: Of 9433 patients
(54.8% male, mean age 41.5 years), 6699 were olanzap-
ine-treated and 2734 quetiapine-treated. After adjusting
for confounding factors, olanzapine-treated patients used
fewer psychotropic agents (-0.36, p < 0.0001) and were
less likely to switch to or augment with other atypical
antipsychotics (odds ratio (OR) = 0.71, 95% conﬁdence
interval (CI) = 0.62 - 0.81). Olanzapine-treated patients
were less likely to be treated with typical antipsychotics
(OR = 0.77, CI = 0.70 - 0.85), mood-stabilizers (OR =
0.84, CI = 0.77 - 0.93), anxiolytics (OR = 0.67, CI = 0.60
- 0.74), or anti-Parkinsonian agents (OR = 0.87, CI =
0.79 - 0.96). There was no between-group difference in
antidepressant or hypnotic use. Total costs for olanzap-
ine-treated patients were lower (-$678, p < 0.0001) as
the result of shorter LOS (-11.4%, p < 0.0001). CON-
CLUSIONS: Compared to quetiapine, olanzapine treat-
ment for hospitalized patients with schizophrenia was
associated with more favorable pharmacotherapy pat-
terns, shorter LOS, and lower costs.
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OBJECTIVES: To examine treatment patterns and
analyze differences in health services utilization and costs
for subjects receiving risperidone, olanzapine or quetiap-
ine. METHODS: This study used administrative claims
data to identify continuously enrolled subjects prescribed
atypical antipsychotics between January 1, 2000 and
December 31, 2000. Subjects were assigned to a diag-
nostic category based on the appearance of two or more
ICD-9 codes for schizophrenia, affective disorder, 
dementia, anxiety or childhood disorders during the
study period. Duration of therapy, compliance, daily
dose, daily average consumption and concomitant med-
ication use were analyzed descriptively. Subjects were
propensity score matched on baseline characteristics for
the purpose of comparing health services utilization and
cost by site of service. RESULTS: Of 6471 study subjects,
average annual days of therapy were nearly equal
between drug groups (184–186 days). However, average
annual days of therapy varied widely by diagnostic con-
dition (181 days for anxiety, 270 days for schizophrenia).
Concomitant use of psychotropic medication was
common for all 3 drugs (81%). Subjects receiving risperi-
done had an average daily dose below the recommended
target dose for schizophrenia as did olanzapine subjects
with bipolar disorder. Daily average consumption
increased slightly for risperidone and quetiapine subjects
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over the follow-up period. After matching, there was no
signiﬁcant difference in health services utilization between
drug groups. However, risperidone subjects had signiﬁ-
cantly lower pharmacy costs (<.0001) and total costs (p
= 0.0181) compared to olanzapine subjects. Subjects with
affective disorders had total costs that were signiﬁcantly
higher compared to subjects with schizophrenia or child-
hood disorders. CONCLUSIONS: Studies comparing
cost and utilization among atypical antipsychotics should
consider the host of factors that may inﬂuence receipt or
regiment of care such as diagnostic condition, duration
of therapy and dosing.
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OBJECTIVE: Factors inﬂuencing atypical antipsychotic
selection include physician preference, and patient char-
acteristics. Studies comparing risperidone, quetiapine,
olanzapine and ziprasidone resulted in inconclusive evi-
dence suggesting superiority of one agent over another.
Amidst concerns over increasing drug expenditures, cost
has become a major issue in the drug sector. Therefore,
the purpose of this study is to model the potential annual
cost savings that may occur as a result of shifting utiliza-
tion from risperidone, quetiapine, and olanzapine to
ziprasidone within the Wisconsin Medicaid population.
METHODS: Retrospective review of Wisconsin Medic-
aid paid prescription claims data from January 1, 2001
to December 31, 2001. Utilization of schizophrenic doses
of risperidone, quetiapine, olanzapine, and ziprasidone
were extracted for this analysis. The main outcomes cal-
culated were cost per unit, mean cost per claim, and total
yearly expenditure per drug. To test the robustness of the
analysis, we modeled the total savings by estimating a
10%, 20% and 50% shift of risperidone, quetiapine and
olanzapine utilization to ziprasidone. RESULTS: Total
number of claims in 2001 for risperidone, quetiapine,
olanzapine and ziprasidone were 41,408, 36,722, 48,647,
and 9,288, respectively. The corresponding annual 
total dollar payouts were $8,705,264, $7,271,390,
$17,081,012, and $1,729,874 respectively. The cost per
claim for ziprasidone ($186.25) was signiﬁcantly lower
than olanzapine ($351.12), quetiapine ($198.01), and
risperidone ($210.23). A 50% shift to ziprasidone would
result in a total cost savings of $4,722,833,70 annually.
CONCLUSION: This analysis suggests that there is a
potential for substantial cost savings within the 
Wisconsin state Medicaid system that would occur as a
results of shifting utilization from other atypical antipsy-
chotics to ziprasidone.
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OBJECTIVES: The economic burden of depression was
estimated at approximately $44 billion in 1990. A sub-
sequent study reﬁned the estimation of the morbidity
costs associated with depressive disorders and revised this
ﬁgure to $53 billion. The objective of this study is 
to provide a 10-year update of the economic burden 
of depression using the same reﬁned methodology.
METHODS: Using a human capital approach we devel-
oped prevalence-based estimates of 3 major cost cate-
gories: 1) direct costs, 2) mortality costs arising from
depression-related suicides, and (3) morbidity costs 
associated with workplace depression. Estimates were
updated to reﬂect 2000 values, using the most current epi-
demiological data for prevalence rates and publicly avail-
able cost data by condition. RESULTS: We estimate that
the total economic burden of depression in 2000 was
$81.5 billion. Of this total, $26.1 billion—32%—are
direct medical costs, $5.4 billion—7%—are mortality
costs, and $49.9 billion—61%—are morbidity costs.
Work absenteeism resulted in $34.5 billion—42% of total
costs, while work cutback costs were $15.4 billion—19%
of total costs. CONCLUSIONS: The economic burden of
depression was $81.5 billion in 2000. Morbidity gener-
ated the largest portion, 61%, of these costs. Future
research investigations will incorporate additional costs
associated with depressive disorders, including the excess
costs of treating comorbid illnesses and the cost burden
of depressed individuals’ family members.
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OBJECTIVES: Depression is a major public health issue
in the United States. It is associated with high morbidity
and mortality. Hence it is important to evaluate its eco-
nomic impact on the U.S. health care system. Information
about the economic burden of depression will help 
in effective utilization and allocation of healthcare
resources. The main outcome measure of this study was
the economic burden of depression in a patient popula-
tion of 703 with a primary diagnosis of depression.
METHODS: A secondary database analysis was con-
ducted using the Medical Expenditure Panel Survey, 1999
(MEPS 99). Patients with primary diagnoses of depres-
sion were identiﬁed using International Classiﬁcation of
Diseases, 9th revision, Clinical Modiﬁcation (ICD 9 CM).
